HeartFlow, Inc. (NASDAQ: HTFL) is a digital health company headquartered in Redwood City, California, that specializes in non-invasive diagnostic solutions for coronary artery disease. Its flagship offering, HeartFlow Analysis, applies advanced computational fluid dynamics and deep learning algorithms to standard coronary CT angiography images. By reconstructing a patient’s 3D arterial anatomy and quantifying fractional flow reserve (FFRCT), the technology provides clinicians with personalized insights into blood flow reduction and lesion-specific ischemia without the need for invasive catheterization.
HeartFlow’s cloud-based platform streamlines the diagnostic workflow by securely transmitting CT image data to its analysis center, where engineers and data scientists generate a detailed physiological assessment. The resulting HeartFlow Analysis report integrates seamlessly with existing imaging systems and offers interactive visualizations that help cardiologists and radiologists prioritize treatment pathways. This capability supports clinical decision-making across diagnostic centers, hospitals and specialized heart institutes.
Founded in 2010 by physicians and engineers from Stanford University, HeartFlow received FDA clearance for its FFRCT technology in 2014 and obtained CE mark approval for European markets shortly thereafter. The company launched a successful initial public offering in February 2021. Since its inception, HeartFlow has forged partnerships with major health systems, academic medical centers and research organizations to validate its technology in large-scale clinical trials and real-world studies.
HeartFlow’s services are available in the United States, Europe, Japan and select other markets, with plans to expand access through strategic collaborations and reimbursement agreements. Under the leadership of President and CEO John H. Stevens, the company continues to invest in research and development, aiming to broaden its digital cardiovascular portfolio and enhance early detection and management of coronary artery disease worldwide.
AI Generated. May Contain Errors.
MarketBeat All Access